Tanios Bekaii-Saab, MD
A precision medicine approach in oncology is entering nationwide clinics and across various tumor types, but many unanswered questions still remain before this strategy can apply to gastrointestinal (GI) cancer treatment, said Tanios Bekaii-Saab, MD.
For example, many patients with colorectal cancer (CRC) remain limited to traditional chemotherapy regimens, aside from a small population of those whose tumors are microsatellite instability-high (MSI-H). This rare subset can derive significant benefit from checkpoint inhibitors.
... to read the full story